Nuveen
TXG icon

Nuveen’s 10x Genomics TXG Stock Holding History

Nuveen’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-18,800
Closed -$4K – 3449
2021
Q2 		$4K Buy
+18,800
New +$3.4M ﹤0.01% 3341

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Nuveen's TXG Position: Q2 2026 in Review

Nuveen increased its 10x Genomics (TXG) stake by 80% in Q2 2026, buying an estimated $13.1M and bringing the position to 1,124,633 shares worth $43.1M. The position accounts for 0.01% of the portfolio, ranked #793.

Nuveen first reported a position in TXG in Q2 2020 and has held it in 25 quarters since. The position peaked at $190M in Q1 2021. 391 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • Nuveen held 1,124,633 shares of 10x Genomics worth $43.1M as of Q2 2026.
  • Nuveen bought 498,837 10x Genomics shares in Q2 2026, an estimated $13.1M.
  • 10x Genomics made up 0.01% of Nuveen's portfolio in Q2 2026, its #793 holding.
  • Nuveen first reported a position in 10x Genomics in Q2 2020 and has held it in 25 quarters since.
  • Nuveen's 10x Genomics position peaked at $190M in Q1 2021.
  • 391 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.